Related Experiment Video

Updated: Apr 14, 2026

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K

Three years of ibrutinib in CLL

Francesco Forconi1

  • 1UNIVERSITY OF SOUTHAMPTON HOSPITAL TRUST.

Blood
|April 18, 2015
PubMed

Insights

Bruton tyrosine kinase inhibitor ibrutinib shows prolonged efficacy and reduced toxicity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma patients. Long-term follow-up confirms sustained benefits with manageable side effects.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are indolent B-cell malignancies.
  • Bruton tyrosine kinase (BTK) inhibitors represent a significant advancement in CLL/SLL treatment.

Purpose of the Study:

  • To report the long-term efficacy and safety of single-agent ibrutinib in CLL/SLL patients.
  • To assess the durability of response and evolving toxicity profile of ibrutinib over a median follow-up of 3 years.

Main Methods:

  • Prospective follow-up of patients with CLL/SLL treated with ibrutinib.
  • Analysis of efficacy endpoints including progression-free survival and overall survival.
  • Evaluation of adverse events and treatment discontinuation rates.

Main Results:

  • Ibrutinib demonstrated prolonged efficacy with sustained patient benefit.
  • Toxicity was limited and showed a reducing trend over time.
  • The median follow-up was 3 years from treatment initiation.

Conclusions:

  • Single-agent ibrutinib offers durable long-term efficacy for CLL/SLL.
  • Ibrutinib exhibits a favorable and manageable safety profile with reduced toxicity over time.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.8K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
17.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804